Appili Therapeutics

Appili Therapeutics Inc. is a clinical-stage biopharmaceutical company based in Halifax, Nova Scotia, Canada. Founded in 2015 by a team of drug development, infectious disease, and commercialization experts, the company was created to address serious global challenges in infectious disease by advancing innovative drug development programs for unmet patient needs. Appili focuses on matching novel drug development programs with clearly defined patient needs, ranging from improvements to established therapies to entirely new classes of anti-infectives. The company's pipeline includes several differentiated anti-infective candidates. LIKMEZ™ (ATI-1501) is a novel oral taste-masked suspension of metronidazole for serious anaerobic and protozoal infections. ATI-1701 is a potential first-in-class live-attenuated vaccine for tularemia, a serious biothreat. ATI-1801 is a novel topical antiparasitic product for disfiguring skin infections such as leishmaniasis. Appili employs a balanced-risk portfolio strategy, combining near-to-market opportunities with transformational science. Appili Therapeutics is publicly listed and operates primarily in Canada while targeting global markets. The company engages in active partnering and in-licensing efforts to expand its clinical programs and accelerate commercialization. Its leadership team is experienced in advancing programs with upside potential, and the company emphasizes a culture of listening to patients, healthcare practitioners, researchers, employees, and shareholders.

Appili Therapeutics Inc. was founded in 2015 by a team of drug development, infectious disease, and commercialization experts. The company was established with the mission to advance the global fight against infectious disease by matching unmet medical needs with opportunities for more effective solutions. From its headquarters in Halifax, Nova Scotia, Canada, Appili has built a pipeline of anti-infective programs that range from near-to-market opportunities to transformational science. The company's strategy has been to deliberately build a balanced-risk portfolio, combining improvements to established therapies with entirely new classes of anti-infectives. Key programs include LIKMEZ™ (ATI-1501), a novel oral taste-masked suspension of metronidazole; ATI-1701, a potential first-in-class live-attenuated vaccine for tularemia; and ATI-1801, a novel topical antiparasitic product for disfiguring skin infections. Appili has engaged in active partnering and in-licensing efforts to expand its clinical programs and accelerate commercialization. The company is publicly listed and continues to operate as a clinical-stage biopharmaceutical company.

• 2015

  Appili Therapeutics Inc. founded by a team of drug development, infectious disease, and commercialization experts.

• LIKMEZ™ (ATI-1501) developed as a novel oral taste-masked suspension of metronidazole.

• ATI-1701 advanced as a potential first-in-class live-attenuated vaccine for tularemia.

• ATI-1801 developed as a novel topical antiparasitic product for disfiguring skin infections.

Clinical-stage biopharmaceutical company focused on anti-infectives and biodefense, with a balanced-risk portfolio strategy.

• LIKMEZ™ (ATI-1501)

  A novel oral taste-masked suspension of metronidazole to treat serious anaerobic and protozoal infections.

• ATI-1701

  A potential first-in-class live-attenuated vaccine for tularemia, a serious biothreat.

• ATI-1801

  A novel topical antiparasitic product to treat disfiguring skin infections around the world.

1. 1Home - Appili Therapeuticsappilitherapeutics.com
2. 2About us - Appili Therapeuticsappilitherapeutics.com
3. 3Appili Therapeutics (Canada) - Wikidatawikidata.org
4. 4Appili Therapeutics Announces Pricing of Overnight Marketed Equity Offeringfinancialpost.com